Before understanding Hengrui Medicine, to share with you the list of leading stocks in the pharmaceutical industry that I have organized, you can click to get: treasure information: the list of leading stocks in the pharmaceutical industry
A, from the company's point of view
Company Profile: Hengrui Medicine's main scope of pharmaceutical research and development, production and sales. The company is not only one of the largest research and production bases of anti-tumor drugs, but also one of the research and production bases of surgical drugs and contrast agents. The company's products cover anti-tumor drugs, surgical anesthesia drugs, special infusion, contrast agents, cardiovascular drugs and many other areas, has formed a relatively complete product layout, and in the industry, including anti-tumor, surgical anesthesia, contrast agents and other areas of the market share can be ranked on the list.
Let's take a look at what the company has to offer
Advantage 1: product structure optimization, promote performance growth
Compared with the previous, the company's revenue structure has been perfected a lot, the growth of the performance of innovative drugs to a certain extent to make up for the decline in the revenue of generic drugs. As for the innovative drug business, the steady increase in revenue from sales of innovative drugs has made the company's performance better and better, and more y improved the company's revenue structure. R&D investment continues to increase, and the overseas R&D layout is gradually increasing.
Advantage 2: Increased R&D efforts to consolidate the company's leading position
The company's expenses spent on R&D have been rising, the company's R&D expenses during the reporting period amounted to RMB 2,580,508,300 yuan, an increase of 38.48% compared with the same period of last year, and accounted for 19.41% of the company's sales revenue. In the research progress of 16 important products of the Company at present, 8 projects have been in clinical phase III trials. During the reporting period, the Company obtained 14 product registration approvals, including 5 innovative drug approvals and 9 generic drug approvals; 41 clinical approvals; and 10 consistency evaluation approvals. In the future, the company's innovative product pipeline will increase in richness, fixing its leading position in innovation and improving its market competitiveness.
Advantage 3: Continuous advancement of internationalization
The company's first international multi-center phase III clinical study, the international multi-center phase III study of Karelizumab in combination with Apatinib in the treatment of advanced hepatocellular carcinoma, has been completed with overseas enrollment, and the preparatory work before the submission of the U.S. FDA BLA/NDA has been initiated. As the company's internationalization strategy continues to promote, the company's R & D team and the domestic team communication and cooperation has been gradually deepened, the company's overseas business scope has been expanding, and is also very hopeful to further expand its own R & D expertise, improve their own innovative products, contributing to the company's performance to be able to thicken the company in the future, the company will gradually from the "Chinese new" towards the "global new". In the future, the company will gradually move from "China's new" to "global new", and is expected to grow into a multinational pharmaceutical platform with international competitiveness.
Because of space constraints, more in-depth reports on Hengrui Pharmaceuticals and risk alerts, I organize in this research report, click to view: in-depth research report on Hengrui Pharmaceuticals review, it is recommended to collect!
Two, from the industry point of view
Industry fundamentals are very good, consumption upgrading and population aging has generated rigid demand, look farther ahead to see or very good:
(1) policy: policy intensively issued, the normalization of band purchasing continued to accelerate the industry differentiation, forcing enterprises to innovation transformation; has established a dynamic adjustment of the health insurance catalog, adopted the Vigorously promote innovative R & D policy, innovative drugs in China has entered a golden period of development, is moving towards the internationalization of the road;
(2) consumer upgrading: because China's economy has been maintained in a state of growth, the entire pharmaceutical industry has ushered in the opportunity to upgrade the consumer demand, with the self-consumption attributes and to circumvent the health care policy of controlling the cost of vaccines and other pharmaceutical segments boom continued.
Three, summarize
Overall, I think Hengrui Pharmaceutical Company, as the pharmaceutical industry's leading innovative drugs, under the opportunity of this industry industry change, is expected to usher in the progress of the day. However, the article may lag behind the development of the times, if you want to know the future of Hengrui more accurate market, click the link below to have a professional investment adviser to help you diagnose the stock, to see the current market of Hengrui medicine whether you can buy or sell: free measurement of the Hengrui medicine still have a chance?